TEL AVIV (Reuters) - Data from the first ALS patients in a clinical trial treated with BrainStorm Cell Therapeutics adult stem cell therapy did not show significant side effects and the treatment has so far proven to be safe, the company said on Tuesday. Israel-based BrainStorm is developing NurOwn for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease, a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. The U.S. Food and Drug Administration last year granted orphan drug designation to NurOwn. ... read more..
U.S. Wants to Buttress Alzheimer's Arsenal by 2025
TUESDAY, Jan. 17 (HealthDay News) -- With the Alzheimer's epidemic predicted to reach crisis proportions as the U.S. population ages, a panel of experts is meeting for two days to draft a plan to combat a disease that is fast emerging as one of the nation's biggest -- and costliest -- health threats. read more..
No comments:
Post a Comment